Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Bofutrelvir (FB2001) in Healthy Subjects and Patients With COVID-19
NCT04766931Phase 1Completed
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Mar 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Compound 7b in coronavirus disease 2019 (COVID-19) (11 arms), sponsored by Frontier Biotechnologies Inc. Primary endpoints: Maximum Tolerable Dose, Number of participants with treatment-related adverse events and 2 more. Started Mar 2021; status: completed.
02
Drugs
Compound 7b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04766931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04766931.